Title Image

Genital herpes

Marketing Status: Ready to launch
Launched or under launch (2012-2016):
Australia & New Zealand, Dubai, Egypt, Finland, Ivory Coast, Jordan, Lebanon, Libya, Malaysia, Mauritania, Middle East, Moldavia & Montenegro, Romania, Serbia, South Africa, Tunisia.


1st Topical Medical Device for the treatment of Genital Herpes and Vaginal Infections

HSV-2 & Vaginal Infection

Physiopathology: Nearly 70% of women harbor the HSV-2 herpes virus which remains dormant in the nerve cells until it gets periodically activated, travelling along the nerves and reaching the vaginal mucosa, causing inflammation and the occasional formation of papules. Clinical signs are mostly related to overgrowth or imbalance in the native microflora, secondary bacterial infection, changes in pH (more alkaline), and mild but chronic manifestations consisting in, often foul-smelling, vaginal discharge, & irritation or burning during urination. Secondary infection causes cellular damage, inflammation, & pain & itching.


Ideal Treatment Approach:

Neutralize free virus particles to stop and prevent further virus multiplication, remove bacteria & other contaminants, stop inflammation, & normalize vaginal pH simultaneously. A mono-target treatment will not be effective.

Currently Available Treatments:     

  • Topical Anti-Virals: none
  • Symptomatic: local antiseptics, anti-inflammatory, pH regulators → recovery takes a very long time as they are mono-target.


VITROBIO’s Completely NEW complete Therapeutic Approach:

VITROBIO conceived a glycerol-based viscous liquid, 18 times more osmotically active than sea water yet NON-IRRITANT (VB-Gy – International patent 1997: PCT/FR99/01340). Further, VB-Gy was rendered filmogen and long-acting (N° PCT/EP2013/061835). Vb-Gy instantly forms a film on the vaginal mucosa, creates a strong outward flow of hypotonic liquid which helps detaching and draining away instantly all the microbial (bacteria & viruses) & other contaminants to stop further infection, as well as the inflammatory cytokines to stop vaginal mucosa inflammation. Being acidic, VB-Gy equally normalizes vaginal pH. These mechanical effects are nearly instant.

Regulatory Status: Being a filmogen liquid bandage, Class IIa Medical Device in Europe.

Product Presentation: 3x10mL or 1x50ml tube. Class IIa medical device for topical application. Totally safe, can be used during pregnancy.

Clinical Efficacy: Full trial published in J Pharmaceutical & Scientific Innovation 2(1), Jan-Feb 2013, 47-51; e-ISSN: 2277-4572.

Marketing Status: Ready to launch (Registered as Medical Device in Europe, Australia)